Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

A potent and orally active HIV-1 integrase inhibitor.

Egbertson MS, Moritz HM, Melamed JY, Han W, Perlow DS, Kuo MS, Embrey M, Vacca JP, Zrada MM, Cortes AR, Wallace A, Leonard Y, Hazuda DJ, Miller MD, Felock PJ, Stillmock KA, Witmer MV, Schleif W, Gabryelski LJ, Moyer G, Ellis JD, Jin L, Xu W, Braun MP, Kassahun K, Tsou NN, Young SD.

Bioorg Med Chem Lett. 2007 Mar 1;17(5):1392-8. Epub 2006 Dec 3.

PMID:
17194584
2.

A series of 5-(5,6)-dihydrouracil substituted 8-hydroxy-[1,6]naphthyridine-7-carboxylic acid 4-fluorobenzylamide inhibitors of HIV-1 integrase and viral replication in cells.

Embrey MW, Wai JS, Funk TW, Homnick CF, Perlow DS, Young SD, Vacca JP, Hazuda DJ, Felock PJ, Stillmock KA, Witmer MV, Moyer G, Schleif WA, Gabryelski LJ, Jin L, Chen IW, Ellis JD, Wong BK, Lin JH, Leonard YM, Tsou NN, Zhuang L.

Bioorg Med Chem Lett. 2005 Oct 15;15(20):4550-4.

PMID:
16102965
3.

Nonpeptide oxytocin antagonists: analogs of L-371,257 with improved potency.

Williams PD, Bock MG, Evans BE, Freidinger RM, Gallicchio SN, Guidotti MT, Jacobson MA, Kuo MS, Levy MR, Lis EV, Michelson SR, Pawluczyk JM, Perlow DS, Pettibone DJ, Quigley AG, Reiss DR, Salvatore C, Stauffer KJ, Woyden CJ.

Bioorg Med Chem Lett. 1999 May 3;9(9):1311-6.

PMID:
10340620
4.

Nonpeptide oxytocin antagonists: potent, orally bioavailable analogs of L-371,257 containing a 1-R-(pyridyl)ethyl ether terminus.

Kuo MS, Bock MG, Freidinger RM, Guidotti MT, Lis EV, Pawluczyk JM, Perlow DS, Pettibone DJ, Quigley AG, Reiss DR, Williams PD, Woyden CJ.

Bioorg Med Chem Lett. 1998 Nov 3;8(21):3081-6.

PMID:
9873680
5.

Synthesis of protected lactam-bridged dipeptides.

Perlow DS, Freidinger RM.

Methods Mol Med. 1999;23:209-25. doi: 10.1385/0-89603-517-4:209.

PMID:
21380900
6.

Conformationally constrained o-tolylpiperazine camphorsulfonamide oxytocin antagonists. Structural modifications that provide high receptor affinity and suggest a bioactive conformation.

Williams PD, Ball RG, Clineschmidt BV, Culberson JC, Erb JM, Freidinger RM, Pawluczyk JM, Perlow DS, Pettibone DJ, Veber DF.

Bioorg Med Chem. 1994 Sep;2(9):971-85.

PMID:
7712132
7.

Development of a novel class of cyclic hexapeptide oxytocin antagonists based on a natural product.

Williams PD, Bock MG, Tung RD, Garsky VM, Perlow DS, Erb JM, Lundell GF, Gould NP, Whitter WL, Hoffman JB, et al.

J Med Chem. 1992 Oct 16;35(21):3905-18.

PMID:
1331448
8.

Renin inhibitors containing conformationally restricted P1-P1' dipeptide mimetics.

Williams PD, Perlow DS, Payne LS, Holloway MK, Siegl PK, Schorn TW, Lynch RJ, Doyle JJ, Strouse JF, Vlasuk GP, et al.

J Med Chem. 1991 Mar;34(3):887-900.

PMID:
2002469
9.

Design of renin inhibitors containing conformationally restricted mimetics of the P1-P1' and P1 through P2' sites.

Williams PD, Payne LS, Perlow DS, Holloway MK, Siegl PK, Schorn TW, Lynch RJ, Doyle JJ, Strouse JF, Vlasuk GP, et al.

Adv Exp Med Biol. 1991;306:325-34. No abstract available.

PMID:
1812722
10.

Design and discovery in the development of long-acting renin inhibitors.

Veber DF, Payne LS, Williams PD, Perlow DS, Lundell GF, Gould NP, Siegl PK, Sweet CS, Freidinger RM.

Biochem Soc Trans. 1990 Dec;18(6):1291-4. No abstract available.

PMID:
2088926
11.

The selectivity of statine-based inhibitors against various human aspartic proteinases.

Jupp RA, Dunn BM, Jacobs JW, Vlasuk G, Arcuri KE, Veber DF, Perlow DS, Payne LS, Boger J, de Laszlo S, et al.

Biochem J. 1990 Feb 1;265(3):871-8.

12.

Synthesis of new peptides based on models of receptor-bound conformation.

Freidinger RM, Brady SF, Paleveda WJ, Perlow DS, Colton CD, Whitter WL, Saperstein R, Brady EJ, Cascieri MA, Veber DF.

Psychopharmacol Ser. 1987;3:12-9. No abstract available.

PMID:
2434945
13.

Conformationally constrained tachykinin analogs which are selective ligands for the eledoisin binding site.

Cascieri MA, Chicchi GG, Freidinger RM, Colton CD, Perlow DS, Williams B, Curtis NR, McKnight AT, Maguire JJ, Veber DF, et al.

Mol Pharmacol. 1986 Jan;29(1):34-8.

PMID:
2418347
14.

Renin inhibitors. Syntheses of subnanomolar, competitive, transition-state analogue inhibitors containing a novel analogue of statine.

Boger J, Payne LS, Perlow DS, Lohr NS, Poe M, Blaine EH, Ulm EH, Schorn TW, LaMont BI, Lin TY, et al.

J Med Chem. 1985 Dec;28(12):1779-90.

PMID:
3906131
15.

Induction of hepatitis A virus-neutralizing antibody by a virus-specific synthetic peptide.

Emini EA, Hughes JV, Perlow DS, Boger J.

J Virol. 1985 Sep;55(3):836-9.

16.

Angiotensin-converting enzyme inhibitors: synthesis and biological activity of acyl tripeptide analogues of enalapril.

Greenlee WJ, Allibone PL, Perlow DS, Patchett AA, Ulm EH, Vassil TC.

J Med Chem. 1985 Apr;28(4):434-42.

PMID:
2984419
17.
18.

A super active cyclic hexapeptide analog of somatostatin.

Veber DF, Saperstein R, Nutt RF, Freidinger RM, Brady SF, Curley P, Perlow DS, Paleveda WJ, Colton CD, Zacchei AG, et al.

Life Sci. 1984 Apr 2;34(14):1371-8.

PMID:
6143233
19.

Conformational modifications of cyclic hexapeptide somatostatin analogs.

Freidinger RM, Perlow DS, Randall WC, Saperstein R, Arison BH, Veber DF.

Int J Pept Protein Res. 1984 Feb;23(2):142-50.

PMID:
6142021
20.

A potent cyclic hexapeptide analogue of somatostatin.

Veber DF, Freidlinger RM, Perlow DS, Paleveda WJ Jr, Holly FW, Strachan RG, Nutt RF, Arison BH, Homnick C, Randall WC, Glitzer MS, Saperstein R, Hirschmann R.

Nature. 1981 Jul 2;292(5818):55-8. No abstract available.

PMID:
6116194
21.

Bioactive conformation of luteinizing hormone-releasing hormone: evidence from a conformationally constrained analog.

Freidinger RM, Veber DF, Perlow DS, Brooks JR, Saperstein R.

Science. 1980 Nov 7;210(4470):656-8.

PMID:
7001627

Supplemental Content

Loading ...
Support Center